• +7 (495) 646-80-76

About the fund

The Genetico investment fund is a corporate venture initiated by Russia’s first public biotech company with a 10-year history of success – the Human Stem Cells Institute (HSCI). The fund is intended to make investments in both separate projects and sector segments in the field of modern biomedical technologies.

The aim of the fund is to benefit from the experience of HSCI’s team and the mechanisms it has developed to create and commercialize products and services as well as to apply the unique expertise which the company has accumulated.

The fund has been created not only to capitalize on HSCI’s strategic advantages but also to provide additional opportunities for participating in the creation of new markets for biomedical products, services and technologies, the sale of licensing rights and companies to major international players. Replicability and global scale are key selection criteria for the fund’s own and multilateral projects.

The funds projects are oriented toward the development of personalized and preventative medicine. The funds scope encompasses the five main focus areas of modern biomedical technologies: regenerative medicine, medical genetics, gene therapy, bio-insurance and biopharmaceuticals.


Achievements and experience of HSCI’s team:

  • Gemabank® – a cord blood stem cell bank created in 2004 which has generated a stable cash flow and made it possible to develop new promising products and services. At present more than 19,500 personal cord blood stem cell samples are held in storage.
  • Neovasculgen® – the first-in-class gene-therapy drug for treatment of Peripheral Arterial Disease (PAD), including Critical Limb Ischemia (CLI). This drug is capable of attaining global distribution.
  • HSCI has assembled a solid portfolio of projects, many of which are helping drive demand for other products and services and augmenting in the scale of the company’s business, creating a solid founded for its sustainable growth (Gemabank, Reprobank, Genetico centers offering genetic diagnostics and consulting services, SPRS-therapy, Neovasculgen® plus a strong pipeline of promising products and services).
  • In 2013 the company opened a new multi-profile laboratory and production complex to provide Russian and international companies working the sector contract services to develop, produce and introduce into practice innovative drugs and technologies.